Company news
Indaptus Therapeutics, Inc. news in 2023
Indaptus Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 5, 2023
Indaptus Therapeutics Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20
September 18, 2023
Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 13, 2023
Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20
August 9, 2023
Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer
August 6, 2023
Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023
Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform
May 8, 2023
Indaptus Therapeutics Receives Brazilian Patent Allowance for Decoy Platform
April 16, 2023
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
March 16, 2023
Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
March 12, 2023
Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
March 6, 2023
Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors
February 13, 2023
Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
February 6, 2023